Everolimus improves progression-free survival for patients with advanced, nonfuctional neuroendocrine tumors

Sunday, September 27, 2015 - 20:30 in Health & Medicine

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors of the lung and gastrointestinal tract.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net